$PBLS

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2026, Parabilis Medicines, Inc. (the “Company”) and Fawzi Benzaghou, M.D., the Company’s Chief Medical Office

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors CAMBRIDGE, Mass., August 25, 2026 – Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for pat

Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research colla

Biotech stocks hit 52-week highs Aug 4, 2026 after Q2 results or regulatory updates. UFP Technologies (UFPT) rose over 25% to $338.70, reporting Q2 net income $20.9M and sales $174M. InfuSystem (INFU) gained 33% to $12.49 on $36.9M Q2 revenue and 2026 guidance. Replimune (REPL) jumped to $13.86 after a favorable BLA opinion. SOPHiA (SOPH) rose to $6.98 with $23.3M Q2 revenue and 2026 outlook. Parabilis (PBLS) reached $36.69.

RA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.

On July 6, 2026, analyst actions included T-Mobile US (TMUS) upgraded to Buy by Bank of America with a $220 target, and Gilead Sciences (GILD) upgraded to Buy by HSBC with a $155 target. Datadog (DDOG) was downgraded to Market Perform by Bernstein; HSBC cut Pfizer (PFE) to Hold. The article also cites mixed rates, gold up ~2%, and Bitcoin above $61,000.

Levy Guy purchased 500,000 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at $20.00 ($10.00M total) across 2 trades on 2026-06-11.

Parabilis Medicines (NASDAQ: PBLS) raised in a June 10 IPO at $20 and closed up 58% on its first day. In its pipeline, zolucatetide is set for Phase 3 in 2027 and is designed to block a Wnt pathway protein-protein interaction. In a Phase 1/2 desmoid tumor study, updated data showed tumor reductions in all 25 evaluable patients, 74% ORR (19 patients), and no high-grade toxicity. Regeneron signed a May 2026 deal providing $50 million cash, $75 million equity, and up to $2.2 billion in milestones.

SEBULSKY ALAN purchased 17,500 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $27.06 ($26.00–$27.67, $0.47M total) across 3 trades over 2026-06-12 to 2026-06-15.